alendronate has been researched along with Dermatomyositis in 9 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Dermatomyositis: A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 6-year-old boy with improving juvenile dermatomyositis (JDM) developed severe and debilitating calcinosis, unresponsive to diltiazem and probenecid." | 5.33 | Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. ( Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M, 2005) |
| " The patient who had dystrophic calcinosis had a dramatic improvement with the introduction of alendronate." | 3.71 | New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. ( Horev, G; Mimouni, M; Mukamel, M, 2001) |
| "Dermatomyositis is an inflammatory autoimmune condition that has also been associated with malignancy." | 2.47 | Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought. ( Fett, N; Liu, RH, 2011) |
| "Malignant melanoma has previously been reported with paraneoplastic syndromes including dermatomyositis." | 1.37 | Metastatic malignant melanoma and dermatomyositis: A paraneoplastic phenomenon. ( Tu, J; Von Nida, J, 2011) |
| "A 6-year-old boy with improving juvenile dermatomyositis (JDM) developed severe and debilitating calcinosis, unresponsive to diltiazem and probenecid." | 1.33 | Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. ( Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M, 2005) |
| "Bone resorption was increased in patients with connective tissue disease and severe dystrophic calcification." | 1.32 | Increased bone resorption and failure to respond to antiresorptive therapy in progressive dystrophic calcification. ( Bresnihan, B; FitzGerald, O; Freaney, R; McKenna, M; Murphy, E, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saini, I | 1 |
| Kalaivani, M | 1 |
| Kabra, SK | 1 |
| Fett, N | 1 |
| Liu, RH | 1 |
| Tu, J | 1 |
| Von Nida, J | 1 |
| Murphy, E | 1 |
| Freaney, R | 1 |
| Bresnihan, B | 1 |
| McKenna, M | 1 |
| FitzGerald, O | 1 |
| Rudge, S | 1 |
| Hailwood, S | 1 |
| Horne, A | 1 |
| Lucas, J | 1 |
| Wu, F | 1 |
| Cundy, T | 1 |
| Ambler, GR | 1 |
| Chaitow, J | 1 |
| Rogers, M | 1 |
| McDonald, DW | 1 |
| Ouvrier, RA | 1 |
| Tau, C | 1 |
| Russo, R | 1 |
| Damiani, D | 1 |
| Mukamel, M | 1 |
| Horev, G | 1 |
| Mimouni, M | 1 |
1 review available for alendronate and Dermatomyositis
| Article | Year |
|---|---|
Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought.
Topics: Alendronate; Antineoplastic Protocols; Arthritis; Breast Neoplasms; Combined Modality Therapy; Derma | 2011 |
1 trial available for alendronate and Dermatomyositis
| Article | Year |
|---|---|
Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
Topics: Administration, Oral; Adolescent; Alendronate; Arthritis, Juvenile; Body Height; Bone Density; Bone | 2005 |
7 other studies available for alendronate and Dermatomyositis
| Article | Year |
|---|---|
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
Topics: Age of Onset; Alendronate; Calcinosis; Child; Child, Preschool; Delayed Diagnosis; Dermatomyositis; | 2016 |
Metastatic malignant melanoma and dermatomyositis: A paraneoplastic phenomenon.
Topics: Adult; Alendronate; Antibodies, Antinuclear; Calcium; Dermatologic Agents; Dermatomyositis; Drug The | 2011 |
Increased bone resorption and failure to respond to antiresorptive therapy in progressive dystrophic calcification.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcino | 2003 |
Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
Topics: Alendronate; Calcinosis; Child; Dermatomyositis; Dose-Response Relationship, Drug; Drug Administrati | 2005 |
[Severe osteoporosis with vertebral crushes in juvenile dermatomyositis. Effect of oral alendronate therapy].
Topics: Adrenal Cortex Hormones; Alendronate; Body Height; Bone Density; Bone Density Conservation Agents; C | 2007 |
Metaphyseal sclerosis associated with bisphosphonate therapy.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Dermatomyositis; Diphosphonates; Huma | 2007 |
New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment.
Topics: Adolescent; Alendronate; Calcinosis; Dermatomyositis; Humans; Interleukin-1; Macrophages; Male; Trea | 2001 |